Cencora, Inc., formerly AmerisourceBergen Corporation, is a global pharmaceutical distribution and services company operating within the Healthcare sector's Medical Distribution industry. The company plays a crucial role in the healthcare supply chain, sourcing and distributing a wide range of pharmaceutical products and offering value-added services to healthcare providers and manufacturers. In its most recent reported quarters, Cencora demonstrated a mixed performance against analyst expectations. For Q3 2025, the company reported actual EPS of $3.84, exceeding the estimated $3.78544, and revenue of $83.73 billion. This followed Q2 2025, where actual EPS was $4.00, surpassing the estimate of $3.83746, with revenue at $80.66 billion. Prior to this, Q1 2025 saw actual EPS of $4.42 against an estimate of $4.09563, and Q4 2024 reported actual EPS of $3.73, beating the estimate of $3.52024. The company has shown a consistent pattern of beating EPS estimates in the last four reported quarters, indicating a positive trend in meeting or exceeding analyst projections. Looking at its historical trajectory, Cencora has generally shown year-over-year growth in its reported earnings and revenues, though specific growth rates are not detailed in the provided data. The company has a track record of meeting or exceeding analyst expectations for earnings per share in recent periods. Recent news indicates that Evercore ISI adjusted its price target for Cencora to $360 from $420 while maintaining an 'Outperform' rating, suggesting a recalibration of near-term valuation expectations. Additionally, Cencora has entered a binding agreement to acquire the retina division of EyeSouth Partners for $1.1 billion, which is expected to bolster its advanced retina care delivery and be slightly accretive to earnings. The company also reaffirmed its fiscal year 2026 adjusted diluted earnings per share outlook. Investors will be watching for the impact of the EyeSouth Partners acquisition on future earnings and the company's ability to maintain its positive EPS beat streak in upcoming quarters, especially as the company has upcoming earnings releases for Q2 2026 and Q3 2026 where revenue estimates are provided but actual results are pending.
